Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

Key Terms

agentic ai technical

Agentic AI refers to computer systems that can make their own decisions and take actions without needing someone to tell them what to do each time. It's like giving a robot a degree of independence to solve problems or achieve goals on its own, which matters because it could change how we work and interact with technology in everyday life.

generative ai technical

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

large language models technical

Large language models are advanced AI systems trained on vast amounts of text to understand and generate human-like writing, like a very fast reader and writer that learns patterns in words and sentences. They matter to investors because they can change how companies operate—automating customer service, speeding analysis, cutting costs, creating new products—and they introduce risks around accuracy, security and regulation that can affect a firm’s revenue and reputation.

health information exchange medical

A health information exchange is a secure electronic system that lets hospitals, clinics and other care providers share patient medical records, test results and treatment histories so the right information is available when and where it’s needed. For investors, HIEs matter because they can reduce healthcare costs, improve patient outcomes and create demand for software, services and data-security solutions—similar to how a shared road network enables businesses to operate more efficiently and scale.

ehr medical

EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.

longitudinal biomarker tracking medical

Longitudinal biomarker tracking is the repeated measurement of biological indicators—like blood proteins, imaging results, or genetic signals—over time to see how a disease or treatment is progressing. For investors, it matters because consistent trends in these markers can provide early evidence that a drug or diagnostic works, reduce uncertainty about clinical outcomes, and influence regulatory or commercial prospects, much like watching a car’s dashboard gauges over a long trip.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities with their diagnostic results to better treat cancer patients

This upgrade connects Tempus’ most advanced agentic AI capabilities directly with real-time patient data inside the Hub environment, scaling how providers utilize, interpret, and act upon complex diagnostic insights. Trusted by thousands of oncologists and care teams, Hub is a secure, AI-enabled platform that delivers actionable patient insights at the point of care. The platform provides seamless access to Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient.

This new architecture introduces an advanced layer of agentic AI-enabled proactive intelligence. Key features rolling out to users include:

• Proactive AI Patient Genomic Insights: Hub can now proactively generate AI patient overviews and integrate deeper AI thinking applied to patients’ Tempus genomic results in the Hub summary page.
• Next-Step Documentation Generation: The platform is expanding to help users instantly generate patient-specific documentation, such as prior authorizations and patient messages, directly pulling in their Tempus data.
• Future Iterations of the Platform: Connecting Tempus Genomics Results with Tempus' Longitudinal Patient Registry or HIE (Health Information Exchange) data to unlock even more complex GenAI workflows.

These capabilities are only possible given the significant investments Tempus has made over the years in building the foundation to connect AI to healthcare data, including (1) Edge, which allows for real-time connection to EHR data and other provider systems, (2) Locker, which allows providers to store their data in a secure environment they control as part of this connectivity; and (3) Air, which allows it to deploy AI models and algorithms in real time to deliver insights at the point of care.

“Our evolution toward an agent-first experience within the Tempus Hub represents a massive win for clinical workflow efficiency,” said Shane Colley, Chief Technology Officer at Tempus. “By bringing our most sophisticated co-pilot intelligence directly into the Hub, we are unlocking the true power of multimodal data to provide seamless, on-demand decision support that meets providers exactly where they are."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ integration of its advanced, next-generation generative AI clinical co-pilot directly in its smart physician platform, Hub. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527419195/en/

Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.